


PHARMACEUTICAL 2022

## Aquestive Therapeutics Inc. Rank 432 of 466









PHARMACEUTICAL 2022



## Aquestive Therapeutics Inc. Rank 432 of 466

The relative strengths and weaknesses of Aquestive Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aquestive Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Aquestive Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 179% points.

The company's Economic Capital Ratio, given in the ranking table, is -206%, being 283% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	47,259
Cost of Goods Sold	0
Intangible Assets	51
Liabilities, Current	21,964
Liabilities, Non-Current	11,553
Other Assets	9,628
Other Compr. Net Income	0
Other Expenses	37,450
Other Liabilities	110,610
Other Net Income	-13,822
Other Revenues	51,255
Property and Equipment	5,055
Research and Development	17,047
Selling, General and Administrative Expense	53,475

Output Variable	Value in 1000 USD
Assets	61,993
Liabilities	144,127
Expenses	107,972
Revenues	51,255
Stockholders Equity	-82,134
Net Income	-70,539
Comprehensive Net Income	-70,539
Economic Capital Ratio	-206%

